Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20900404 | 0.84 | MEN1 (0.63) | LTA4HBLMKMT2AMEN1ACE2 | |
| SCHEMBL14217283 | 0.84 | MEN1 (0.63) | LTA4HBLMKMT2AMEN1ACE2 | |
| SCHEMBL16828262 | 0.82 | LTA4H (0.43) | LTA4HBLMKMT2AMEN1ACE2 | |
| SCHEMBL12413859 | 0.81 | CYP1A2 (0.52) | LTA4HBLMKMT2AMEN1ACE2 | |
| SCHEMBL19069567 | 0.81 | CASP2 (0.59) | LTA4HBLMKMT2AMEN1ACE2 | |
| SCHEMBL21261702 | 0.81 | ALDH1A1 (0.43) | LTA4HBLMKMT2AMEN1ACE2 | |
| SCHEMBL18588225 | 0.79 | KDM4E (0.58) | LTA4HBLMACE2ITGB3ITGA2B | |
| SCHEMBL14930734 | 0.79 | KDM4E (0.58) | LTA4HBLMACE2ITGB3ITGA2B | |
| SCHEMBL15871482 | 0.79 | FOLH1 (0.43) | KMT2AMEN1FOLH1ALB | |
| SCHEMBL20528860 | 0.79 | FOLH1 (0.49) | FOLH1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045523-B2 | Formulation of growth hormone albumin-binder conjugate | NOVO NORDISK HEALTHCARE AG (CH) | 2021-06-29 | — | — | US | disclosed |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-04 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045523-B2 | Formulation of growth hormone albumin-binder conjugate | ALB, SHBG, SERPINA6 | LTA4H 1657/4885BLM 4507/4885KMT2A 3876/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | LTA4H 1577/4885BLM 2900/4885KMT2A 3466/4885 |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | LTA4H 1577/4885BLM 2900/4885KMT2A 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.